Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023

Oral Presentation at SNO will feature updated results from the Phase 1/2 EOGBM1-18/ROSALIE study Paris, France – November 13 th, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform , today announced it will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (the EOGBM1-18/ROSALIE study), in an oral presentation at the Society for Neuro-Oncology (SNO) 28 th Annual Meeting which will be held in Vancouver, British Columbia, Canada on November 15-19, 2023. Oral presentation details – Abstract CTIM-25 Title: EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the phase 1/2 EOGBM1-18/ROSALIE study (NCT04116658) Presenting Author : Prof. David Reardon, M.D., Professor of Medicine at Harvard Medical School, and Clinical Director for Dana Farber Cancer Institute Session Name : Abstract Concurrent Session: Clinical Trials – Immunologic Session Date and Time : Friday, November 17, 2023, at 8:35 AM PST Location : Room 109-110 Link to abstract published in a supplement to Neuro-Oncology, the Official Journal of the Society for Neuro-Oncology, can be found here . The slides from the oral presentation will be available on Enterome’s website after the Meeting. About ROSALIE ROSALIE (EOGBM1-18) is a multicenter, open-label, first-in-human, Phase 1/2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab, Opdivo ® ) +/- bevacizumab for the treatment of patients with first progression/recurrence of glioblastoma. The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of the combination in 100 patients enrolled at 10 clinical sites in Europe and the US. For more information on the Phase 1/2 trial of EO2401 in recurrent glioblastoma, please refer to ClinicalTrials.gov Identifier: NCT04116658 About OncoMimics ™ OncoMimics ™ immunotherapies are designed to activate pre-existing effector memory T cells that target bacterial (non-self) peptides, which are strongly cross-reactive against selected Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid, targeted cytotoxic response against cancer. Download the press release (.pdf format) Enterome Headquarters 94/96 avenue Ledru-Rollin 75011 Paris – France Tel: +33 (0)1 75 77 27 85 Email: [email protected] Metro Station: Ledru-Rollin (Line 8) About About us Leadership Investors Pipeline Pipeline OncoMimics™ Platform Our Mimicry Approach Our Drug Discovery Platform Clinical Trials B cell malignancies Glioblastoma Adrenal tumors Colorectal Cancer News & Events Press Releases Press Coverage Webinars Presentations & Posters Relevant Literature Careers Our Values Careers Cookies Policy Privacy Policy Legal Notice

The release as fetched from its publisher. enterome.com ↗